SGK1 and metabolic disease: These compounds have shown significant inhibitory effects, suggesting their potential value of clinical application in multiple diseases, including carcinomas, metabolic disorders, brain ischemia and depression, etc. SGK1 inhibitors also exhibit potent inhibitory effects in fibrotic diseases, and their therapeutic potential in cGVHD need to be studied in the future since fibrosis is one of the major phases in the pathogenesis of cGVHD.